Search
Search
Close this search box.

Blood Biomarkers in Pediatric Kidney Transplant Recipients

NCT_ID: NCT05477082

Clinical Trial Link

Brief Summaries

Sequence: 30583392
Description The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody mediated rejection. The study hypothesizes that blood gene expression profile and donor-derived cell-free DNA biomarkers (omnigraf) can be used to predict acute rejection and monitor its response to treatment.

Studies

Study First Submitted Date 2022-07-25
Study First Posted Date 2022-07-28
Last Update Posted Date 2023-08-01
Start Month Year August 1, 2023
Primary Completion Month Year May 27, 2024
Verification Month Year July 2023
Verification Date 2023-07-31
Last Update Posted Date 2023-08-01

Facilities

Sequence: 198803460
Name University of Minnesota
City Minneapolis
State Minnesota
Zip 55455
Country United States

Facility Contacts

Sequence: 27966318
Facility Id 198803460
Contact Type primary
Name Amy Hanson
Email amhanson@umn.edu
Phone 612-626-4424

Conditions

Sequence: 51857806
Name Rejection of Kidney Allograft
Downcase Name rejection of kidney allograft

Id Information

Sequence: 39907551
Id Source org_study_id
Id Value PEDS-2022-30750

Countries

Sequence: 42305717
Name United States
Removed False

Interventions

Sequence: 52178016
Intervention Type Other
Name Observational group
Description Includes blood draws and data collection only

Keywords

Sequence: 79358030 Sequence: 79358031 Sequence: 79358032 Sequence: 79358033 Sequence: 79358034
Name acute rejection Name kidney transplant Name pediatric Name biomarker Name cell free DNA
Downcase Name acute rejection Downcase Name kidney transplant Downcase Name pediatric Downcase Name biomarker Downcase Name cell free dna

Design Outcomes

Sequence: 176361966 Sequence: 176361967
Outcome Type primary Outcome Type primary
Measure Biopsy-proven acute rejection Measure Clinical resolution of rejection
Time Frame 7 days from baseline Time Frame 8 weeks from baseline
Description Yes or No assessment Description Yes or No assessment; defined as improvement in serum creatinine to a value that is within 25% of baseline serum creatinine

Sponsors

Sequence: 48029237
Agency Class OTHER
Lead Or Collaborator lead
Name University of Minnesota

Overall Officials

Sequence: 29102903
Role Principal Investigator
Name Sarah Kizilbash, MD
Affiliation University of Minnesota

Central Contacts

Sequence: 11944384
Contact Type primary
Name Amy Hanson
Phone 612-626-4424
Email amhanson@umn.edu
Role Contact

Eligibilities

Sequence: 30582173
Sampling Method Non-Probability Sample
Gender All
Minimum Age N/A
Maximum Age 21 Years
Healthy Volunteers No
Population Pediatric kidney transplant recipients, ages < 21 years, scheduled to undergo a for-cause kidney biopsy to rule out graft rejection
Criteria Inclusion Criteria: Kidney transplant recipients Participants undergoing a for-cause kidney biopsy to rule out graft rejection Ages 21 years and less Exclusion Criteria: Participants who have opted out of research Patients, less than 18 years of age, whose parents or legal guardians are illiterate and cannot read. Participants, 18 years and older, who are illiterate and cannot read. Participants, less than 18 years of age, whose parents or legal guardians do not speak English. Participants, 18 years and older, who do not speak English Participants who are pregnant as confirmed by medical records
Adult True
Child True
Older Adult False

Calculated Values

Sequence: 253856461
Number Of Facilities 1
Registered In Calendar Year 2022
Were Results Reported False
Has Us Facility True
Has Single Facility True
Maximum Age Num 21
Maximum Age Unit Years
Number Of Primary Outcomes To Measure 2

Designs

Sequence: 30330338
Observational Model Cohort
Time Perspective Prospective

Responsible Parties

Sequence: 28709128
Responsible Party Type Sponsor